Additional Details

  • Platform Clinical Study for Conquering Scleroderma

    University of Alabama - Division of Pulmonary and Critical Care Medicine
    Birmingham AL. 35294
    View Details

  • Platform Clinical Study for Conquering Scleroderma

    Columbia University Medical Center
    New York NY. 10032
    View Details

  • Platform Clinical Study for Conquering Scleroderma

    Cedars-Sinai Medical Center
    Los Angeles CA. 90048
    View Details

  • Platform Clinical Study for Conquering Scleroderma

    Northwell Health
    Great Neck NY. 11021
    View Details

  • Platform Clinical Study for Conquering Scleroderma

    University of Kansas School of Medicine
    Kansas City KS. 66160
    View Details

  • Platform Clinical Study for Conquering Scleroderma

    Cleveland Clinic
    Cleveland OH. 44195
    View Details

  • Platform Clinical Study for Conquering Scleroderma

    University of Pennsylvania
    Philadelphia PA. 19104
    View Details

  • Platform Clinical Study for Conquering Scleroderma

    Mayo Clinic
    Rochester MN. 55905
    View Details

  • Platform Clinical Study for Conquering Scleroderma

    Massachusetts General Hospital
    Boston MA. 02114
    View Details

  • Platform Clinical Study for Conquering Scleroderma

    Hospital for Special Surgery
    New York NY. 10021
    View Details

  • Platform Clinical Study for Conquering Scleroderma

    Emory University School of Medicine
    Atlanta GA. 30322
    View Details

  • Platform Clinical Study for Conquering Scleroderma

    Duke University Medical Center
    Durham NC. 27710
    View Details

  • Platform Clinical Study for Conquering Scleroderma

    University of California, Los Angeles (UCLA) Ronald Reagan Medical Center
    Los Angeles CA. 90095-7436
    View Details

  • Platform Clinical Study for Conquering Scleroderma

    Stanford University Medical Center
    Palo Alto CA. 94305
    View Details

  • Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation

    University of South Florida/ Tampa General Hospital
    Tampa FL. 33606
    View Details

  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    Central Florida Pulmonary Group, P.A. (CFPG) - Downtown Orlando
    Orlando FL. 32803-5727
    View Details

  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    University of Texas Southwestern Medical Center
    Dallas TX. 75235-6243
    View Details

  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    University of Oklahoma Health Sciences Center (OUHSC)
    Oklahoma City OK. 73104-5417
    View Details

  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    Southeastern Research Center
    Winston-Salem NC. 27103-4007
    View Details

  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    Metroplex Pulmonary and Sleep Center
    McKinney TX. 75069-1898
    View Details